As Orphan Drugs Gain More Attention, FDA Releases Development Guidance
This article was originally published in The Pink Sheet Daily
Straightforward draft document seems aimed at entities that have limited experience working with the agency.
You may also be interested in...
Agency specifies several approaches to augment safety assessment in a new draft guidance, which also encourages participation by patients and their advocates in the drug development process.
FDA wants to advance PRO projects through the user fee reauthorization, but ironically is having difficulty quantifying how much support it might need.
BioMarin showed that the Vimizim BLA did not have enough data to prove that clinical and commercial sites are different. That’s not the same as concluding there is no difference between the sites, FDA said.